35results about How to "Reduce bone resorption" patented technology

Compositions and methods for treating osteoporosis using the compositions are disclosed where the compositions have reduced GI toxicity and improved bio-availability and include a bisphosphonate and zwitterionic phospholipid.

The invention discloses a method for preparing a continuous gentle micro-nano structure on a titanium substrate from the outside to the inside through femtosecond laser processing and then anodizing. The method comprises the three steps of polishing, femtosecond laser processing and anodizing. The continuous gentle micro-nano structure prepared through the method is good in repeatability, high in stability and controllable in size and has excellent mechanical properties and biological properties. Due to the fact that the continuous gentle micro-nano structure is formed by partially converting an implantation material and no obvious separatrix exists between the structure and the substrate, the combination strength of the structure and the titanium substrate is high; in addition, the continuous gentle concave pit structure is more approximate a natural bone structure, and osteoblast adhesion growing is facilitated.

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.

A self-stabilizing porous interbody fusion cage comprises a columnar main body, a bone grafting window, a clamping part and a porous reticulate body; the columnar main body is of a columnar hollow frame structure; the bone grafting window is arranged in the inner cavity of the columnar main body and is fixedly connected with the columnar main body through the clamping part; and the porous reticulate body is arranged in a space between the columnar main body and the bone grafting window. The preparation method of the self-stabilizing porous interbody fusion cage comprises the steps: firstly, arranging a plurality of fusion cages with gradient specifications; secondly, establishing a spine three-dimensional model, and obtaining parameters; thirdly, carrying out a pre-operation simulation operation, and simulating an evaluation effect; and fourthly, adopting 3D printing processing molding. The method has the advantage that personalized customization is performed according to the medical image data of the target cone segment of a patient. The upper and lower end faces of the columnar main body are respectively matched with the surface contours of the upper and lower end plates of the cone. The self-stabilizing porous interbody fusion cage conforms to the human cervical vertebra vertebral end plate form, enlarges the vertebral contact area, avoids local stress concentration of the contact surface, and reduces the sinking and collapsing risks of the implant.

The BioRoot® anatomic endosseous dental implant begins as a block of yttria-stabilized, zirconia oxide (MOL3% Y3ZrO2) that is milled and processed into a single piece dental implant with a custom built abutment to which a dental prosthesis can be attached after a three to four month osseointegration period, with unique retention devices that can be round, ovoid, or oblong-shaped, of any size desired with a varied number of holes (See Drawings FIGS. 1, 1 and 2, FIGS. 2, 1 and 2, and FIGS. 3, 1 and 2) which through the osseointegration process will become anchors between the implant surface and the alveolar walls of the extracted tooth root socket that minimize bone resorption, increase bone-to-implant contact, increase initial implant stability and enhance overall osseointegration.

The invention discloses a medicine for treating osteoporosis, which is prepared mainly from total daidzein, total epimedium flavones, and added crystalline cellulose,sodium carboxymethylstarch through the steps of palletizing, drying, and granulating.

The invention discloses a composition for improving the immunity. In the composition, a weight ratio of Ossotide to bone marrow peptide is 1-5:1; and a certain weight part of zinc lactate can be added. A preparation method for the composition comprises the following steps of: collecting fetal bovine marrow, washing and sterilizing the fetal bovine marrow, separating fat from the fetal bovine marrow, and separating protein from active substances; performing enzymolysis on the fetal bovine marrow twice, concentrating and drying the fetal bovine marrow to obtain the bone marrow peptide; collecting beef bones, washing and crushing the beef bones, and allowing the beef bones to enter a distillation retort to perform extraction; separating the fat from an extract, separating a supernatant, performing enzymolysis on the supernatant twice, and concentrating and drying the supernatant to obtain the Ossotide; and mixing the bone marrow peptide, the Ossotide and the zinc lactate uniformly in a proportion to obtain a formulation which is acceptable by a human body. The composition can improve the immunity of the human body, effectively resist the attack of diseases outside, and slow the speed of aging.

The invention discloses an application of gastrodin for preventing and treating osteoporosis, gastrodin has nontoxic effect to osteoblast precursor cells, and has no influence on cell proliferation; gastrodin has protection effect on apoptosis of MC3T3-E1 caused by hydrogen peroxide; improves oxidative stress state induced by H2O2 in a differentiation process of the MC3T3-E1, and has protective function on MC3T3-E1 osteogenic differentiation inhibition caused by H2O2; besides, gastrodin can inhibit expression of a bone absorption factor. Therefore, gastrodin can play a role of protecting osteoporosis through improvement on osteoblast apoptosis and differentiation inhibition, and indirect inhibition of osteoclast activation. In an osteoporosis model of castrated mice, gastrodin can improve oxidative stress state in serum, improves a bone micro-structure of cancellous bone of distal femur and lumbar vertebra, and increases osteogenesis rate of distal femur, so that gastrodin can improve bone micro-structure by inhibiting the oxidative stress state and has the effect for preventing and treating osteoporosis.

The invention features polypeptides that include an extracellular ActRlla variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRlla variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving bone damage, e.g., primary osteoporosis, secondary osteoporosis, osteopenia, osteopetrosis, facture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss.

The invention relates to application of chickpea sprout extracts in medicines for preventing deficiency of estrogen. The chickpea sprout extracts are chickpea sprout isoflavone extracts, are used as estrogen receptor regulator, and are used for preparing medicines and health care products which are used for preventing or treating climacteric syndrome and osteoporosis. Tests show that the chickpea sprout isoflavone extracts can directly act onto the uterus of a patient, can remarkably increase estradiol level in blood serum, have regulating and controlling effects to a hypothalamus-hypophysis- neuroendocrine system, remarkably increase thighbone density and relative bone volume of an SD (Sprague Dawley) rat without the ovary, increase the thickness of bone trabecula, reduce separating degree of the bone trabecula, decrease the quantity of osteoclast, can alleviate bone loss of the thighbone of the rat due to the fact that the ovary of the rat is removed, increase bearing capacity of the thighbone, play an important role in regulating internal secretion conditions of middle-aged and elderly women after menopause, improving menopause symptoms such as hot flash, palpitate, skin dryness and the like and reducing possibility of osteoporosis, and lay a foundation in industrial development of functional factors of chickpeas.

The invention discloses an application of ginsenoside Rb2 to protection of an osteoblast precursor cell. The ginsenoside Rb2 is non-toxic to the osteoblast precursor cell, does not influence cell proliferation, has a protecting effect on apoptosis of the osteoblast precursor cell (MC3T3-E1) caused by hydrogen peroxide (H2O2), can be used for improving the H2O2 induced oxidative stress status in the differentiation process, has a protecting effect on inhibition of MC3T3-E1 osteogenic differentiation caused by H2O2, and can inhibit expression of bone absorption factors, so that osteoporosis can be protected by improving osteoblast apoptosis and differential inhibition and indirectly inhibiting osteoclast activation. The ginsenoside Rb2 can improve the oxidative stress status in serum, improve the trabecular microstructure of the distal femur and the fourth lumbar vertebra, and reduce the mineral deposition rate of the distal femur, which indicates that the ginsenoside Rb2 can improve the bone microstructure by inhibiting oxidative stress to play the effect of preventing and treating osteoporosis.

The invention discloses a composition for promoting bone health. The composition comprises the following raw material components in parts by mass: 3-15 parts of cucumber seeds, 3-15 parts of chicken shells, 1-6 parts of human placenta, 1-4 parts of amygdalus pedunculata oil, 0.5-3 parts of eucommia seed oil, 0.3-1 part of hydrolyzed yolk powder and 0.1-1 part of a calcium nutrition enhancer. The composition for promoting bone health prepared by the invention has the obvious effects of enhancing the physique of children and middle-aged and elderly people and changing the sub-health state of children and middle-aged and elderly people, and has a remarkable improvement effect on bone health diseases, even can be comparable with related conventional treatment medicines to a certain extent, andis expected to be developed into a hot market product for improving the bone health diseases.

The invention relates to a heparin alendronate sodium conjugate synthetic method and drugs in the field of medicine. The heparin alendronate sodium conjugate synthetic method comprises the steps: step1, firstly, dissolving 2-chloro-4,6-dimethoxy-1,3,5-triazine in tetrahydrofuran, adding 4-methylmorpholine, stirring for 1-2 h at room temperature, collecting by filtration and washing a precipitatefive times with THF, and thus then obtaining a DMT-MM condensation agent after 48 h of vacuum drying; and step 2, adding heparin and the condensation agent into ultra-pure water, stirring for 1 h, then adding an alendronate sodium solution into the mixed solution of heparin and the condensation agent, carrying out reaction for 24-48 h, pouring the solution into a dialysis bag, dialysing for 48-72h, changing water once every 4 h, finally, freeze-drying the product obtained from dialysis, and thus obtaining the heparin alendronate sodium conjugate drugs. In the method, alendronate sodium is modified by heparin, so the solubility of the drugs is increased, the bioavailability is improved, the cytotoxicity is reduced and the formation of osteoclasts is effectively inhibited.

The invention discloses an application of myricetrin for preventing and treating osteoporosis. Myricetrin is free from toxic effect on human mesenchymal stem cells, does not affect cell proliferation, has a protective effect on apoptosis of the human mesenchymal stem cells caused by H2O2, improves the oxidative stress state induced by H2O2 in the differentiation process, has a protective effect on ossifying differential inhibition of human bone mesenchymal stem cells caused by H2O2, has an inhibiting effect on enhancement of adipogenic differentiation of human bone mesenchymal stem cells caused by H2O2, and can inhibit expression of bone absorption factors so as to improve apoptosis and differential inhibition of the human mesenchymal stem cells and indirectly inhibit osteoclast activation to protect osteoporosis. In an osteoporotic model of a castrated mouse, the myricetrin can improve the oxidative stress state in serum and improve the bone micro-structures of the cancellous bone at the distal femur and the fourth lumbar vertebra, so that the myricetrin can improve the bone micro-structure by inhibiting oxidative stress and exerting the effect of preventing and treating osteoporosis.

The invention discloses a novel LDH nanosheet material, an AL/LDH material, a preparing method of the two materials, and application of the materials in preparing an osteanagenesis material for treating femoral head necrosis, bone defects and/or osteoporosis. The prepared LDH components are Mg-Al-Yb single-layer hydroxide, and through the mutual effect of hydrophilic groups, alendronate sodium isloaded on the surface of LDH. LDH and AL/LDH are used for accelerating osteanagenesis of an osteonecrosis area, and AL/LDH can promote the increase of the density of the bone of the necrosis area while accelerating the osteanagenesis of the implanted part of the material. Currently, a main method for clinically treating femoral head necrosis in the early period involves that core decompression iscombined with bone transplantation, and AL/LDH and LDH can be used as the bone transplantation material after core decompression; moreover, for patients with the whole body suffering from osteoporosis, AL/LDH is utilized as the material for filling the osteonecrosis area, and increase of the bone density of the whole body is promoted.

The invention discloses an exosome-loaded improved porous implant suitable for oral implantation. The implant comprises a compact layer, a porous layer and a functional layer. The inner core is a compact layer, the outer layer of the compact layer of the inner core is a communicating porous layer, bone tissue growth is facilitated, and a support is provided for the functional layer; the outer layer of the porous layer is provided with threads, and the upper section of the porous layer is provided with Morse taper connection, so that micro gaps at the joint of the implant and an abutment can be reduced, the stability of the implant is improved, and bone resorption is effectively reduced; and pores of the porous layer are filled with the functional layer, the functional layer contains a gelatin compound loaded with a Schwann cell-derived exosome, and the exosome-gelatin compound can uniformly release the Schwann cell-derived exosome to surrounding bone tissues and has the functions of repairing damaged nerves, regulating tissue inflammation and promoting bone regeneration. The implant has the effects of repairing injured nerves, regulating tissue inflammation and promoting bone regeneration, effectively solves the problem of bone resorption after implantation, and can improve the stability at the initial stage of implantation to a certain extent.

The invention relates to an application of prawnella in treatment or prevention of osteoporosis. The P.histicola bacteria are used as symbiotic bacteria in normal human intestinal tracts and have excellent safety, animal experiments on estrogen-deficient mice find that the P.histacola can be used for preventing bone mass loss of the mice; the imbalance of intestinal flora caused by estrogen deficiency is regulated, the expression of inflammatory factors is inhibited, the intestinal permeability increase caused by estrogen deficiency is reduced, then inflammatory factors in the intestinal tractwall are reduced, differentiation, maturation and activation of osteoclasts guided by RANKL are inhibited; the P.histacola bacteria have effects of osteoporosis resistance, bone absorption reducing,bone mass loss inhibition and estrogen deficiency osteoporosis resistance, and can meet the requirements of long-term taking, economy, safety and no side effect required by osteoporosis prevention andtreatment as the micro-ecological preparation.

The invention discloses an application of saikoside a in prevention and treatment of osteoporosis. According to the application of saikoside a in the prevention and treatment of osteoporosis, saikoside a is characterized by being no toxic to human mesenchymal stem cells, not influencing cell proliferation, but preventing human mesenchymal stem cells from apoptosis caused by hydrogen peroxide, improving H2O2 induced oxidative stress state during differentiation, preventing human mesenchymal stem cells from differential inhibition caused by H2O2, inhibiting raising of adipogenic differentiation of human mesenchymal stem cells caused by H2O2, and also inhibiting the expression of bone resorption factors, so as to reduce apoptosis and differential inhibition of human mesenchymal stem cells and indirectly inhibit osteoclast activation to prevent osteoporosis. According to a castrated mice osteoporosis model, saikoside a can improve the oxidative stress of serum and can also improve cancellous bone microstructures of distal femur and the fourth lumbar vertebra; and therefore, saikoside a can be used for preparing a medicine for preventing and treating osteoporosis.

The invention discloses application of a bone absorption marker CTX in an abnormal glucose metabolism occurrence prediction system. The prediction system comprises a base line bone absorption maker CTX variable input sub module and an analysis module, wherein the analysis module can build a tertile group on the basis of a variable input by the base line bone absorption marker CTX variable input sub module; the abnormal glucose metabolism occurrence risk of the base line CTX middle tertile people group is the lowest; the abnormal glucose metabolism occurrence risk of the base line CTX highest tertile people group is the highest. The prediction system has the advantages that the great guidance significance is realized on the use of anti-bone-absorption medicines on the treatment of high-riskpeople groups with osteoporosis accompanied with or not accompanied with diabetes. The bone absorption of the patient with osteoporosis is positively reduced; meanwhile, the glucose metabolism effectis considered; the bone absorption activity cannot be excessively reduced.

The invention discloses a health-care food composition for increasing the bone mass and inhibiting the bone loss. The health-care food composition is prepared from auxiliary materials and an effectivecomponent, and the effective component is blueberries. Formulas of different proportions are adopted according to people of different ages, through the product, the bone mass is increased, increasingof the bone volume is promoted, osteoblast proliferation and differentiation are promoted, osteoclast proliferation and differentiation are inhibited, the bone loss in an osteoporosis model is reduced, and thus the health-care food composition is used for preventing and treating osteoporosis.